SEC Company Response from Verrica Pharmaceuticals Inc. (VRCA) (CIK 0001660334) (VRCA) — Dec 19, 2025
Verrica Pharmaceuticals Inc. (VRCA) (CIK 0001660334)
Date: Dec. 19, 2025 · CIK: 0001660334 · Accession: 0001193125-25-326765
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292140
Letter
RE: Verrica Pharmaceuticals Inc. Registration Statement on Form S-3 File No. 333-292140 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, Verrica Pharmaceuticals Inc. (the “ Registrant ”) hereby requests that the U.S. Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on December 23, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Mark Ballantyne and Divakar Gupta of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Mark Ballantyne at (703) 456-8084, or in his absence, Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474.
Verrica Pharmaceuticals Inc. 44 W. Gay St. Suite 400 West Chester, PA 19380 December 19, 2025 VIA EDGAR Division of Corporation Finance Office of Technology United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C.
Very truly yours,
VERRICA PHARMACEUTICALS INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Verrica Pharmaceuticals Inc. 44 W. Gay St. Suite 400 West Chester, PA 19380 December 19, 2025 VIA EDGAR Division of Corporation Finance Office of Technology United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Verrica Pharmaceuticals Inc. Registration Statement on Form S-3 File No. 333-292140 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, Verrica Pharmaceuticals Inc. (the “ Registrant ”) hereby requests that the U.S. Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on December 23, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Mark Ballantyne and Divakar Gupta of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Mark Ballantyne at (703) 456-8084, or in his absence, Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474. Very truly yours, VERRICA PHARMACEUTICALS INC. By: /s/ David Zawitz Name: David Zawitz Title: Chief Operating Officer cc: Mark Ballantyne, Cooley LLP Divakar Gupta, Cooley LLP